NYSE - Delayed Quote USD

Organon & Co. (OGN)

Compare
14.72
+0.59
+(4.18%)
At close: April 2 at 4:00:02 PM EDT
14.30
-0.42
(-2.85%)
Pre-Market: 9:23:42 AM EDT
Currency in USD All numbers in thousands
Download
Breakdown
TTM
12/31/2024
12/31/2023
12/31/2022
12/31/2021
Total Revenue
6,403,000
6,403,000
6,263,000
6,174,000
6,304,000
Cost of Revenue
2,688,000
2,688,000
2,515,000
2,294,000
2,382,000
Gross Profit
3,715,000
3,715,000
3,748,000
3,880,000
3,922,000
Operating Expense
2,229,000
2,229,000
2,421,000
2,175,000
2,007,000
Operating Income
1,486,000
1,486,000
1,327,000
1,705,000
1,915,000
Net Non Operating Interest Income Expense
-520,000
-520,000
-527,000
-422,000
-258,000
Other Income Expense
-159,000
-159,000
-127,000
-161,000
-128,000
Pretax Income
807,000
807,000
673,000
1,122,000
1,529,000
Tax Provision
-57,000
-57,000
-350,000
205,000
178,000
Net Income Common Stockholders
864,000
864,000
1,023,000
917,000
1,351,000
Diluted NI Available to Com Stockholders
864,000
864,000
1,023,000
917,000
1,351,000
Basic EPS
3.36
3.36
4.01
3.61
5.33
Diluted EPS
3.33
3.33
3.99
3.59
5.31
Basic Average Shares
257,046
257,046
255,239
254,082
253,537.94
Diluted Average Shares
259,152
259,152
256,270
255,169
254,192.70
Total Expenses
4,917,000
4,917,000
4,936,000
4,469,000
4,389,000
Net Income from Continuing & Discontinued Operation
864,000
864,000
1,023,000
917,000
1,351,000
Normalized Income
973,020
973,020
1,111,480
1,036,282
1,449,077.83
Interest Expense
520,000
520,000
527,000
422,000
258,000
Net Interest Income
-520,000
-520,000
-527,000
-422,000
-258,000
EBIT
1,327,000
1,327,000
1,200,000
1,544,000
1,787,000
EBITDA
1,604,000
1,604,000
1,436,000
1,756,000
1,982,000
Reconciled Cost of Revenue
2,688,000
2,688,000
2,515,000
2,294,000
2,382,000
Reconciled Depreciation
277,000
277,000
236,000
212,000
195,000
Net Income from Continuing Operation Net Minority Interest
864,000
864,000
1,023,000
917,000
1,351,000
Total Unusual Items Excluding Goodwill
-138,000
-138,000
-112,000
-146,000
-111,000
Total Unusual Items
-138,000
-138,000
-112,000
-146,000
-111,000
Normalized EBITDA
1,742,000
1,742,000
1,548,000
1,902,000
2,093,000
Tax Rate for Calcs
0
0
0
0
0
Tax Effect of Unusual Items
-28,980
-28,980
-23,520
-26,718
-12,922.17
12/31/2021 - 5/14/2021

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade

Related Tickers

MRK Merck & Co., Inc.
86.60
-0.60%
 
GSK GSK plc
37.64
-0.61%
 
BMY Bristol-Myers Squibb Company
59.60
+0.08%
 
SNY Sanofi
53.95
-0.72%
 
BIIB Biogen Inc.
131.32
-0.54%
 
AMGN Amgen Inc.
305.70
-0.40%
 
PFE Pfizer Inc.
24.70
+0.65%
 
NVS Novartis AG
110.77
+1.06%
 
AZN AstraZeneca PLC
72.22
-0.52%
 
GRFS Grifols, S.A.
7.49
+7.61%